NOV120101 (Poziotinib)

DRUG3 trials

Sponsors

National OncoVenture, Hanmi Pharmaceutical Company Limited

Conditions

Adenocarcinoma of Lung Stage IIIBAdenocarcinoma of Lung Stage IVIncreased Drug ResistanceMetastatic Breast Cancer

Phase 2

NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors

CompletedNCT01718847

National OncoVentureIncreased Drug Resistance

Start: 2013-01-31End: 2014-09-30Updated: 2015-08-14

NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma

TerminatedNCT01819428

National OncoVentureAdenocarcinoma of Lung Stage IIIB, Adenocarcinoma of Lung Stage IV

Start: 2013-03-31End: 2015-11-30Updated: 2016-03-01

Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens

CompletedNCT02418689

Hanmi Pharmaceutical Company LimitedMetastatic Breast Cancer

Start: 2015-04-30End: 2021-04-30Updated: 2022-01-20

Related Papers

Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib.

2020-08-284 citations

Role of HER2 copy number amplification and PI3K pathway as a biomarker for patients with HER2+ MBC treating with Poziotinib, pan-HER TKI.

Journal of Clinical Oncology2018-05-201 citations

Abstract P2-09-21: Molecular alterations and poziotinib, a pan-HER inhibitor efficacy in human epidermal growth factor receptor 2(HER2) positive breast cancers: Combined exploratory biomarker analysis from phase II clinical trial of poziotinib for refractory HER2 positive breast cancer(BC) patients

Cancer Research2018-02-15

Abstract OT3-01-10: A prospective, open-label, single-arm, multi-center, phase II exploratory study to evaluate the efficacy and safety of poziotinib (NOV120101) in patients with HER2-positive metastatic breast cancer who have received at least two prior HER2-directed regimens

Cancer Research2016-02-152 citations

A phase II, single-arm, efficacy and safety study of poziotinib (NOV120101) in Korean patients with advanced or metastatic lung adenocarcinoma who have acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

Journal of Clinical Oncology2015-05-20